Table 2.
Values for 23 analytes in samples drawn before the initiation of treatment of GVHD in patients from cohort 1
| Area under ROC curve‡ (P) | |||||
|---|---|---|---|---|---|
| Normal median values (Q1-Q3) (N = 48*) | Values in patients with acute GVHD (Q1-Q3) (N = 74†) | Peak grade 2b-4 (n = 25) vs grade 2a (n = 49) | Peak grade 3-4 (n = 12) vs grade 2 (n = 62) | NRM at 1 y (n = 12) vs not NRM | |
| HGF | 115 (90-129) | 182 (135-341) | 0.63 (.06) | 0.72 (.01)§ | 0.81 (.001)§ |
| IFNγ | 0.3 (0.3-0.3) | 2.93 (1.85-4.06) | 0.61 (.05) | 0.51 (.53) | 0.61 (.13) |
| IL1α | 2.2 (1.0-4.4) | 1.00 (1.00-1.00) | 0.52 (.30) | 0.51 (.53) | 0.57 (.10) |
| IL2 | 35.7 (16.0-62.8) | 22.8 (3.6-64.9) | 0.71 (.001)§ | 0.61 (.23) | 0.60 (.19) |
| IL6 | 19.1 (8.7-36.6) | 27.2 (17.0-47.5) | 0.69 (.005) | 0.75 (.02)§ | 0.73 (.03)§ |
| IL8 | 3.8 (1.7-8.9) | 34.4 (22.9-58.9) | 0.69 (.001) | 0.67 (.02) | 0.67 (.03) |
| IL10 | 90.9 (48.5-164.5) | 11.9 (5.7-22.3) | 0.45 (.81) | 0.69 (.47) | 0.60 (.69) |
| IL12p70 | 10.2 (6.8-17.7) | 39.2 (16.8-74.6) | 0.55 (.64) | 0.50 (.96) | 0.55 (.52) |
| IL17 | 9.1 (2.7-13.6) | 9.42 (1.00-29.67) | 0.63 (.11) | 0.51 (.58) | 0.48 (.87) |
| IL18 | 18.1 (11.7-21.0) | 64.8 (32.4-124.0) | 0.64 (.07) | 0.67 (.06) | 0.63 (.10) |
| IL21 | 115 (8-177) | 10.6 (8.0-75.5) | 0.62 (.09) | 0.51 (.92) | 0.61 (.17) |
| IL22 | 240 (240-240) | 240 (240-240) | 0.52 (.20) | 0.52 (.40) | 0.52 (.40) |
| IL32 | 12.3 (8.0-31.0) | 8.00 (8.00-8.00) | 0.52 (.60) | 0.48 (.98) | 0.49 (.94) |
| IL33 | 496 (280-840) | 499 (240-1107) | 0.64 (.04) | 0.48 (.84) | 0.56 (.34) |
| IL2Ra | 120 (120-120) | 195 (120-449) | 0.58 (.39) | 0.49 (.91) | 0.57 (.68) |
| sTNFR1 | 188 (120-448) | 1720 (1080-2900) | 0.61 (.17) | 0.73 (.007)§ | 0.73 (.005)§ |
| TNFα | 20.7 (4.8-37.4) | 1.52 (1.00-5.14) | 0.48 (.97) | 0.71 (.03)§ | 0.68 (.10) |
| TSLP | 2.0 (2.0-17.8) | 2.00 (2.00-2.00) | 0.55 (.67) | 0.54 (.94) | 0.54 (.79) |
| TGF β1 | 19.0 (11.2-33.) | 39.4 (16.4-72.9) | 0.67 (.03) | 0.54 (.46) | 0.52 (.71) |
| CRP | 329 (168-776) | 8880 (1860-20680) | 0.71 (.0009)§ | 0.68 (.03) | 0.68 (.03) |
| TIM3 | 2290 (1860-2670) | 5570 (2960-10150) | 0.66 (.01) | 0.75 (.002)§ | 0.66 (.03) |
| REG3a | 21.5 (15.2-28.8) | 36.7 (20.5-83.7) | 0.62 (.22) | 0.56 (.52) | 0.71 (.009)§ |
| ST2 | 15.0 (15.0-21.5) | 21.1 (15.0-58.4) | 0.77 (.0002)§ | 0.81 (.002)§ | 0.77 (.002)§ |
The operating characteristics for predicting more severe outcomes in patients with acute GVHD, and the relevant P values, are provided for each analyte.
*
TIM3 concentrations were measured in samples from 48 healthy controls, and REG3a and ST2 concentrations were measured in 47 healthy controls.
†
REG3a and ST2 concentrations were measured in samples from 62 patients with acute GVHD.
‡
ROC curves were derived for less vs more severe GVHD and for deaths before relapse vs survival among patients with GVHD.
§
With area under an ROC curve ≥0.70.